Evidence map›Paper›PMID 25592182›Full record

ArticleAddiction science & clinical practice2015

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.

Aaron D Fox, Jeronimo Maradiaga, Linda Weiss, Jennifer Sanchez, Joanna L Starrels, Chinazo O Cunningham

Open access · goldAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aaron D FoxAlbert Einstein College of Medicine, Bronx, NY, 10461, USA. adfox@montefiore.org.
Jeronimo MaradiagaAlbert Einstein College of Medicine, Bronx, NY, 10461, USA. jmaradia@montefiore.org.
Linda WeissNew York Academy of Medicine, New York, NY, 10029, USA. Lweiss@nyam.org.
Jennifer SanchezMontefiore Medical Center, Bronx, NY, 10467, USA. jennsanc@montefiore.org.
Joanna L StarrelsAlbert Einstein College of Medicine, Bronx, NY, 10461, USA. jostarre@montefiore.org.
Chinazo O CunninghamAlbert Einstein College of Medicine, Bronx, NY, 10461, USA. ccunning@montefiore.org.
Albert Einstein College of Medicine · USMontefiore Medical Center · USNew York Academy of Medicine · US

Funding

Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI KIM, MIMI Y · 2003 to 2013
$18.6M
Abstinence Reinforcing Contingency Management to Suppress HIV Viral LoadR01DA032110 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUNNINGHAM, CHINAZO · 2011 to 2015
$3.6M
HIV and Substance Abuse Clinical Addiction Research and Education (CARE) ProgramR25DA023021 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ARNSTEN, JULIA H. · 2007 to 2014
$2.7M
Buprenorphine Facilitated Access and Supportive Treatment in Former InmatesK23DA034541 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI FOX, AARON D · 2012 to 2016
$913k
Mentoring researchers on drug abuse and HIVK24DA036955 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUNNINGHAM, CHINAZO · 2014 to 2019
$911k
Intervention to Promote Opioid Treatment Agreements in Primary CareK23DA027719 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STARRELS, JOANNA L. · 2010 to 2014
$909k
NEURAL BASIS FOR OPIATE AND MESCALINE TOXIC BEHAVIORR01DA003454 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CONNOR, JOHN D · 1985 to 1985
–
NIAID NIH HHS AI-51519NIAID NIH HHS P30 AI051519NIDA NIH HHS K23 DA027719NIDA NIH HHS K23DA03454NIDA NIH HHS K23 DA034541NIDA NIH HHS K24 DA036955NIDA NIH HHS K24DA036955NIDA NIH HHS R01 DA032110NIDA NIH HHS R25 DA023021NIDA NIH HHS R25DA023021
6 · The paper itself

Abstract

backgroundThe United States has the highest rate of incarceration in the world (937 per 100,000 adults). Approximately one-third of heroin users pass through correctional facilities annually. Few receive medication assisted treatment (MAT; either methadone or buprenorphine) for opioid use disorder during incarceration, and nearly three-quarters relapse to heroin use within 3 months of release. This qualitative study investigated barriers to and facilitators of buprenorphine maintenance treatment (BMT) following release from incarceration ("re-entry").

methodsWe conducted 21 semistructured interviews of former inmates with opioid use disorder recruited from addiction treatment settings. Interviews were audio-recorded, transcribed, and analyzed using a grounded theory approach. Themes that emerged upon iterative readings of transcripts were discussed by the research team.

resultsParticipants reported adverse re-entry conditions, including persistent exposure to drug use and stressful life events, which were perceived to contribute to opioid relapse and affected addiction treatment decisions during re-entry. Themes that emerged relating to BMT included: 1) reliance on willpower; 2) fear of dependency on medications; 3) variable exposure to buprenorphine; and 4) acceptability of BMT following relapse. Willpower was perceived to be more important for recovery than medications. Many participants experienced painful withdrawal from methadone during incarceration and were fearful that using MAT would lead to opioid tolerance and painful withdrawal again in the future. Participants reported both positive and negative experiences taking illicit buprenorphine, which affected interest in BMT. Overall, BMT was perceived to be a good treatment option for opioid use disorder that could reduce the risk of re-incarceration.

conclusionsBMT was perceived to be acceptable, but former inmates with opioid use disorder may be reluctant to utilize BMT upon re-entry. Factors limiting utilization of BMT could be mitigated though policy change or interventions. Policies of the criminal justice system (e.g., forced detoxification) may be dissuading former inmates from utilizing effective treatments for opioid use disorder. Interventions that improve education and access to BMT for former inmates with opioid use disorder could facilitate entrance into treatment. Both policy changes and interventions are urgently needed to reduce the negative consequences of opioid relapse following re-entry.

Indexed as

BuprenorphineFemaleGoalsHeroin DependenceHumansInterviews as TopicMaleMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersPrisonersQualitative ResearchRacial GroupsRecurrenceSelf EfficacyUnited StatesBuprenorphine

Identifiers

PMID25592182
PMCPMC4410477
OpenAlexW2145215274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.